[A21-95] Angiotensin II acetate (hypotension) - Benefit assessment according to §35a Social Code Book V
Last updated 06.01.2022
Project no.:
A21-95
Commission:
Commission awarded on 15.07.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Heart and circulation
Refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite appropriate restoration of volume and use of catecholamines or other available vasoconstrictive therapies.
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-147 | Angiotensin II acetate (refractory hypotension in distributive shock) - Addendum to Commission A21-95 | Commission completed |
Federal Joint Committee (G-BA)
2022-01-06 A G-BA decision was published.